K. Abid

Discipline

Psychologie (2) Philosophie (1)

Type de document

Articles (25)

Co-auteur

Date

Source

Mot-clé

Human beings (15) protéine (11) Patients (9) Patients (9) Hepatitis C virus (8) Expression (8) Tumors (7) Cells (7) plasma (7) métabolisme (6) Diagnosis (6) Treatment (6) RNA (6) Metabolism (6) Liver (6) Hepatitis C (6) Diagnosis (6) Metabolism (6) effet (5) Neuroendocrine tumors (5) Pheochromocytoma (5) Tumors (5) lipide (4) gène (4) maladie (4) adulte (4) Inhibitors (4) Tissues (4) Manufacturers' agents (4) Fatty degeneration (4)

Documents écrit par K. Abid (25) | parle de K. Abid (0)

Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma.
P.J. Eugster et al. (1 sept. 2022)
Quantification of serotonin and eight of its metabolites in plasma of healthy volunteers by mass spectrometry.
P.J. Eugster et al. (10 août 2022)
Low number of neurosecretory vesicles in neuroblastoma impairs massive catecholamine release and prevents hypertension.
A. Mühlethaler-Mottet et al. (2022)
eIF4E3 forms an active eIF4F complex during stresses (eIF4FS) targeting mTOR and re-programs the translatome.
B. Weiss et al. (21 mai 2021)
The noradrenergic profile of plasma metanephrine in neuroblastoma patients is reproduced in xenograft mice models and arise from PNMT downregulation.
K. Abid et al. (5 janv. 2021)
A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting.
R. Mansi et al. (5 août 2020)
Cellular effects of AP102, a somatostatin analog with balanced affinities for the hSSTR2 and hSSTR5 receptors.
J. Streuli et al.
Pheochromocytoma Masked by Mutation in the TH Gene.
K. Abid et al.
Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?
E. Grouzmann et al. (2015)
Enzyme and acid deconjugation of plasma sulfated metanephrines.
M. Glauser et al. (2014)
Synthetic calibrators for the analysis of total metanephrines in urine: revisiting the conditions of hydrolysis.
J. Simonin et al. (2012)
Cellular factors implicated in prion replication.
K. Abid et al. (3 juin 2010)
Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.
K. Abid et al. (2009)
The prion strain phenomenon: molecular basis and unprecedented features.
R. Morales et al.
In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
R. Liu et al.
The intriguing prion disorders
K. Abid et al.
Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.
T. Pietschmann et al. (9 mai 2006)
Protein misfolding cyclic amplification for diagnosis and prion propagation studies.
J. Castilla et al. (2006)
An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation.
K. Abid et al.
Lack of in vivo blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus.
L. Rubbia-Brandt et al.
The 4,977-base pair common deletion of mitochondrial DNA is not associated with steatosis in chronic hepatitis C patients.
P. Latorre et al.
Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis.
R. Quadri et al.
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.
L. Rubbia-Brandt et al.
A novel hepatitis C virus (HCV) subtype from Somalia and its classification into HCV clade 3.
K. Abid et al.
Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance.
K. Abid et al. (3 mars 2000)